MicroGenDX, a national pioneer in molecular diagnostics, announced on September 2, 2025, its adoption of Illumina's MiSeq i100 Plus sequencing platform. This integration has enabled MicroGenDX to cut its next-generation sequencing (NGS) turnaround time to just 24 hours from sample receipt, accelerating patient care.
The MiSeq i100 Plus, part of Illumina's compact and low-cost gene sequencing devices, is proving its value in clinical settings where rapid results are critical for life-saving decisions. This adoption highlights the instrument's efficiency and reliability in delivering timely and accurate genomic data.
This customer win for Illumina validates the benefits of the MiSeq i100 Plus, particularly its ability to streamline workflows and improve operational efficiency for diagnostic labs. Such adoptions can drive further market penetration and demonstrate the practical impact of Illumina's innovative sequencing technologies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.